Company profile · free preview

Johnson & Johnson

JNJ · Updated 10/26/2026

Revenue

$94.2B

Fiscal 2025

Net income

$26.8B

Fiscal 2025

Free cash flow

$19.7B

Fiscal 2025

Net cash / (debt)

—

Fiscal 2025

Five-year financials

Fiscal year20252024202320222021
Revenue$94.2B$88.8B$80.0B$93.8B$82.6B
Net income$26.8B$14.1B$17.9B$20.9B$14.7B
Diluted EPS—————
Operating cash flow$24.5B$24.3B$21.2B$23.4B$23.5B
Free cash flow$19.7B$19.8B$17.2B$19.8B$20.2B
Cash$19.7B$24.1B$12.9B$14.5B$14.0B
Total debt—————

Where the cash went

Cumulative, fiscal 2021–2025, straight from the reported cash-flow statements.

Reinvested in capex

17.3%

of operating cash flow

Returned to owners

—

of free cash flow (buybacks + dividends)

Diluted share count

—

change 2021–2025

Capital expenditure $20.3BBar width = share of $116.9B operating cash flow
Operating cash flow$116.9B
Capital expenditure($20.3B)
Free cash flow$96.7B
Share buybacks—
Dividends paid—
Acquisitions (net)—
Net debt issued / (repaid)—
Stock-based compensation (non-cash)—

"—" means a year didn't report that line, so no total is shown rather than an estimate.

SEC filings

  • 10-K · period 2025-12-282026-02-11EDGAR

Ask anything about Johnson & Johnson's filings

"What changed since last year?" "Where is the cash going?" Get answers drawn straight from the filings.

Start researching free

More companies